Ocular Therapeutix (OCUL) Gross Margin (2014 - 2026)

Ocular Therapeutix's quarterly Gross Margin came in at 87.68% in Q1 2026, up 11993.0% year-on-year from N/an in Q1 2025, and up 3864.93% quarter-over-quarter from 2.21% in Q4 2025.

Ocular Therapeutix has reported Gross Margin for 13 years, with the latest figure at 87.68% in Q1 2026.

  • For the quarter ending Q1 2026, Gross Margin rose 11993.0% year-over-year to 87.68%; the trailing twelve-month figure through Mar 2026 stood at 65.4% (up 1144.0% YoY), and the FY2025 full-year result was 3.79%, down 9497.0% from the prior year.
  • Gross Margin for Q1 2026 stood at 87.68%, up from 2.21% in the prior quarter.
  • The five-year high for Gross Margin was 92.81% in Q4 2022, with the low at 147.65% in Q4 2023.
  • Average Gross Margin over 5 years is 45.57%, with a median of 85.56% recorded in 2025.
  • Year-over-year, Gross Margin tumbled 24046 bps in 2023 and surged 24044 bps in 2024.
  • Tracing OCUL's Gross Margin over 5 years: stood at 92.81% in 2022, then slumped by 259 bps to 147.65% in 2023, then surged by 163 bps to 92.8% in 2024, then sank by 98 bps to 2.21% in 2025, then jumped by 3865 bps to 87.68% in 2026.
  • The last three Gross Margin figures came in at 87.68% (Q1 2026), 2.21% (Q4 2025), and 87.8% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 79.04%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 86.85%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 91.79%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 82.22%
10 Ocular Therapeutix 1.99 Bn 1.99 Bn 9.46 Mn 87.68%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 87.68%
Dec 31, 2025 2.21%
Sep 30, 2025 87.80%
Jun 30, 2025 85.56%
Mar 31, 2025 -32.25%
Dec 31, 2024 92.80%
Sep 30, 2024 31.46%
Jun 30, 2024 90.82%
Mar 31, 2024 91.02%
Dec 31, 2023 -147.65%
Sep 30, 2023 38.23%
Jun 30, 2023 26.56%
Mar 31, 2023 90.92%
Dec 31, 2022 92.81%
Sep 30, 2022 14.87%
Jun 30, 2022 90.58%
Mar 31, 2022 31.27%
Dec 31, 2021 91.00%
Sep 30, 2021 89.22%
Jun 30, 2021 28.39%
Mar 31, 2021 -10.13%
Dec 31, 2020 341.12%
Sep 30, 2020 -10.96%
Jun 30, 2020 -292.16%
Mar 31, 2020 -173.28%
Dec 31, 2019 765.96%
Sep 30, 2019 -717.49%
Jun 30, 2019 -1,011.54%
Mar 31, 2019 -580.28%
Dec 31, 2018 76.79%
Sep 30, 2018 76.91%
Jun 30, 2018 -33.80%
Mar 31, 2018 -110.88%
Dec 31, 2017 -85.42%
Sep 30, 2017 -519.12%
Jun 30, 2017 -1,459.82%
Mar 31, 2017 -1,168.84%
Dec 31, 2016 -1,149.51%
Sep 30, 2016 76.52%
Jun 30, 2016 76.19%
Mar 31, 2016 76.20%
Dec 31, 2015 -820.05%
Sep 30, 2015 -121.95%
Jun 30, 2015 -126.80%
Mar 31, 2015 76.47%
Dec 31, 2014 -280.40%
Sep 30, 2014 77.62%
Jun 30, 2014 79.38%
Mar 31, 2014 -1,048.15%